These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 30300989)

  • 1. Renovations Needed: the FDA's Floor/Ceiling Framework, Preemption, and the Opioid Epidemic.
    Abrams MR
    Mich Law Rev; 2018 Oct; 117(1):143-71. PubMed ID: 30300989
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bad medicine: prescription drugs, preemption, and the potential for a no-fault fix.
    Smirniotopoulos A
    Rev Law Soc Change; 2012; 35(4):793-862. PubMed ID: 22363960
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The US Opioid Crisis: Current Federal and State Legal Issues.
    Soelberg CD; Brown RE; Du Vivier D; Meyer JE; Ramachandran BK
    Anesth Analg; 2017 Nov; 125(5):1675-1681. PubMed ID: 29049113
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The FDA's Approach to the Prescription Opioid Problem.
    Woodcock J; Throckmorton DC
    Clin Pharmacol Ther; 2018 Jun; 103(6):954-955. PubMed ID: 29570773
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Companies to pay $39.5m in OxyContin and Risperdal cases.
    McCarthy M
    BMJ; 2015 Dec; 351():h7018. PubMed ID: 26721284
    [No Abstract]   [Full Text] [Related]  

  • 6. Buckman extended: federal preemption of state fraud-on-the-FDA statutes.
    Gaddis CA
    Food Drug Law J; 2014; 69(1):113-36, iii. PubMed ID: 24772688
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Curbing the opioid epidemic in the United States: the risk evaluation and mitigation strategy (REMS).
    Nelson LS; Perrone J
    JAMA; 2012 Aug; 308(5):457-8. PubMed ID: 22851109
    [No Abstract]   [Full Text] [Related]  

  • 8. Rehabilitating opioid regulation: a prescription for the FDA's next proposal of an opioid risk evaluation and mitigation strategy (REMS).
    Homenko H
    Health Matrix Clevel; 2012; 22(1):273-313. PubMed ID: 22616548
    [No Abstract]   [Full Text] [Related]  

  • 9. Tort reform by regulation: FDA prescription drug labeling rules and preemption of state tort claims.
    Moreland MP
    J Health Life Sci Law; 2007; 1(1):39, 41-62. PubMed ID: 18610730
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FDA's expanding postmarket authority to monitor and publicize food and consumer health product risks: the need for procedural safeguards to reduce "transparency" policy harms in the post-9/11 regulatory environment.
    Roller ST; Pippins RR; Ngai JW
    Food Drug Law J; 2009; 64(3):577-98. PubMed ID: 19999646
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pain treatment, drug diversion, and the casualties of war.
    Burgess F
    Pain Med; 2006; 7(6):474-5. PubMed ID: 17112360
    [No Abstract]   [Full Text] [Related]  

  • 12. Should preemption apply in a pharmaceutical context? An analysis of the preemption debate and what regulatory compliance statutes contribute to the discussion.
    Surprenant JA
    Fordham Law Rev; 2008 Oct; 77(1):327-63. PubMed ID: 18982554
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Export of pharmaceuticals and medical devices under the federal Food, Drug & Cosmetic Act: FDA's striking change in interpretation post-Shelhigh.
    Basile EM; Tolomeo D; Gluck E
    Food Drug Law J; 2009; 64(1):149-69. PubMed ID: 19998744
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Zohydro approval by food and drug administration: controversial or frightening?
    Manchikanti L; Atluri S; Candido KD; Boswell MV; Simopoulos TT; Grider JS; Falco FJ; Hirsch JA
    Pain Physician; 2014; 17(4):E437-50. PubMed ID: 25054396
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Solving the Opioid Epidemic in Ohio.
    Leduc L
    J Law Health; 2019; 32(1):110-134. PubMed ID: 31087832
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Compensating Pharmaceutical Injuries in the Absence of Fault.
    Rowin MA
    Food Drug Law J; 2014; 69(3):447-70, ii. PubMed ID: 27382858
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vaccine liability in the Supreme Court: forging a social compact.
    Kraemer JD; Gostin LO
    JAMA; 2011 May; 305(18):1900-1. PubMed ID: 21558521
    [No Abstract]   [Full Text] [Related]  

  • 18. The FDA and the tort system: postmarketing surveillance, compensation, and the role of litigation.
    Struve CT
    Yale J Health Policy Law Ethics; 2005; 5(2):587-669. PubMed ID: 16052895
    [No Abstract]   [Full Text] [Related]  

  • 19. Preventing the next crisis: six critical questions about the opioid epidemic that need answers.
    Scanlon DP; Hollenbeak CS
    Am J Manag Care; 2019 Jul; 25(13 Suppl):S234-S238. PubMed ID: 31361431
    [No Abstract]   [Full Text] [Related]  

  • 20. Failure of enforcement controlled substance laws in health policy for prescribing opiate medications: a painful assessment of morbidity and mortality.
    Miller NS
    Am J Ther; 2006; 13(6):527-33. PubMed ID: 17122534
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.